Patient Characteristics and Chemotherapy Regimens
| Characteristic | PET4 patients (n = 80) |
|---|---|
| Median age (y) | 53 (range, 19–78) |
| Sex, men/women | 52/28 |
| Ann Arbor stage (n) | |
| I–II | 10 (13%) |
| III–IV | 70 (87%) |
| Standard IPI score (n) | |
| Low risk (0–1 factor) | 17 (21%) |
| Low–intermediate risk (2 factors) | 14 (18%) |
| High–intermediate risk (3 factors) | 29 (36%) |
| High risk (4–5 factors) | 20 (25%) |
| Chemotherapy regimens (n) | |
| CHOP | 3 (4%) |
| R-CHOP | 21 (26%) |
| ACVBP/ACE | 37 (46%) |
| R-ACVBP | 19 (24%) |
| Autologous stem cell transplantation (n) | 34 (43%) |
IPI = International Prognostic Index; CHOP = cyclophosphamide, hydroxydaunomycin, vincristine, prednisone; ACVBP = adriamycin, cyclophosphamide, vindesine, bleomycin, prednisone; ACE = adriamycin, cyclophosphamide, etoposide; R = rituximab.